Autoimmune Cytopenia and BcR Inhibitors

Conditions

• Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ibrutinib ou idelalisib — DRUG
  treatment by ibrutinib or idelalisib for autoimmune cytopenia

Study Details

Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

Key Dates

Start date

Jul 21, 2017

Status verified

Mar 2018

Primary completion

Jul 31, 2018

Completion

Jul 31, 2018

Study Design

Enrollment

40 participants (actual)

Arms

• Arm: active CLL treated with ibrutinib or idelalisib for CAI
  Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia. The progressive nature of contemporary CAI LLC is not a criterion of exclusion.

Primary Outcome Measure

Efficacy of B-cell receptor inhibitors on autoimmune cytopenia (AIC) [ Time Frame: 1 year ]